Drug interactions
Hydrochlorothiazide-telmisartan + Irbesartan
Severity: Major
Hydrochlorothiazide-telmisartan and Irbesartan: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Irbesartan is another angiotensin receptor blocker, so combining it with telmisartan duplicates therapy. Dual blockade of the renin-angiotensin system raises the risk of hypotension, hyperkalemia and renal dysfunction without proven added benefit.
What this interaction means in plain words
Hydrochlorothiazide-telmisartan and Irbesartan can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Hydrochlorothiazide-telmisartan belongs to Cardiovascular; Irbesartan belongs to Cardiovascular.
Why it happens
Duplicate angiotensin II type 1 receptor blockade produces additive effects on blood pressure, aldosterone suppression and renal hemodynamics.
What to do
Avoid using two ARBs together and keep a single agent. If both were taken, monitor potassium, creatinine and blood pressure.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Hydrochlorothiazide-telmisartan and Irbesartan, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Hydrochlorothiazide-telmisartan
- Aliskiren + Hydrochlorothiazide-telmisartan Contraindicated
- Dofetilide + Hydrochlorothiazide-telmisartan Contraindicated
- Hydrochlorothiazide-telmisartan + Sparsentan Contraindicated
- Aldesleukin + Hydrochlorothiazide-telmisartan Major
- Amifostine + Hydrochlorothiazide-telmisartan Major
- Amiloride + Hydrochlorothiazide-telmisartan Major
Other interactions of Irbesartan
- Aliskiren + Irbesartan Contraindicated
- Irbesartan + Sparsentan Contraindicated
- Amifostine + Irbesartan Major
- Amiloride + Irbesartan Major
- Amlodipine-benazepril + Irbesartan Major
- Amlodipine-hydrochlorothiazide-valsartan + Irbesartan Major
Frequently asked questions
Can I take Hydrochlorothiazide-telmisartan with Irbesartan?
MediHelp rates the interaction as major. Hydrochlorothiazide-telmisartan and Irbesartan can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Irbesartan is another angiotensin receptor blocker, so combining it with telmisartan duplicates therapy. Dual blockade of the renin-angiotensin system raises the risk of hypotension, hyperkalemia and renal dysfunction without proven added benefit.
How serious is the interaction between Hydrochlorothiazide-telmisartan and Irbesartan?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid using two ARBs together and keep a single agent. If both were taken, monitor potassium, creatinine and blood pressure.
What other medicines interact with Hydrochlorothiazide-telmisartan?
MediHelp also lists interactions of Hydrochlorothiazide-telmisartan with, for example, Aliskiren, Dofetilide, Sparsentan. The full list is on the Hydrochlorothiazide-telmisartan page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
